Trans health care faces new obstacle; FDA report details problems at plant involved in eye drop recall

A looming change to U.S. telehealth rules could curtail trans people's access to gender-affirming care.

March 31, 2023 Check out STAT+

Sponsored By

Adobe Trans health care, already under attack, faces new obstacle with end of Covid public health emergency The end of the Covid public health emergency on May 11 could further jeopardize trans people's access to gender-affirming care. By Theresa Gaffney STAT+ | FDA report details problems at Global Pharma plant involved in eye drop recall The FDA inspection occurred shortly after Global Pharma Healthcare recalled two different brands of eye drops over contamination concerns. By Ed Silverman STAT+ | Inflation caused a sizable drop in net drug prices in late 2022, analysis finds After considering inflation, net prices fell 8.5%, compared, which was the largest quarterly decline in real terms seen by the analysts. By Ed Silverman Adobe Genetic differences in breast tumors may contribute to racial disparities Social factors like access had been linked to worse results for Black patients. A study suggests biological differences may also play a role. By Angus Chen STAT+ | Opinion: 3 keys to successful biopharma-academia drug development collaborations Many sponsored research collaborations that hope to tap into academia fail. But there are ways to make them work. By Dave Greenwald

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Daily Recap? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser